Table 1 Clinical characteristics of the patients studied
UPN | Age/sex | Disease | Duration of lung disease (months) | Medication at presentation | FVC/DLCO |
|---|---|---|---|---|---|
1 | 77/M | RA-UIP | 0 | No therapy | 75.3/47.2 |
2 | 71/F | RA-UIP | 12 | PDN/AZA/NAC | 68.7/22.1 |
3 | 75/F | RA-UIP | 0 | No therapy | 89.7/34.8 |
4 | 72/M | RA-UIP | 0 | MTX-LEFLUNEMIDE* | 119.3/68.4 |
5 | 76/F | RA-UIP | 6 | PDN/AZA/NAC | 82.8/60.1 |
6 | 50/F | RA-UIP | 12 | PDN/AZA/NAC | 94.5/49.6 |
7 | 81/F | RA-UIP | 0 | No therapy | 76.5/32 |
8 | 74/M | IPF | 0 | No therapy | 70/70 |
9 | 78/M | IPF | 0 | No therapy | 41.6/25 |
10 | 82/M | IPF | 0 | No therapy | 75.6/38.5 |
11 | 85/M | IPF | 0 | No therapy | 88/31 |
12 | 70/M | IPF | 0 | No therapy | 83/58 |
13 | 72/M | IPF | 0 | No therapy | 75/45 |